Blog posts • Jul 11, 2014 23:45 BST
Markus Peck-Radosavljevic, EASL Secretary General highlights hepatitis C data anticipated at the International Liver CongressTM 2014. He discusses what this means for patients and the post-graduate courses for Hepatitis C treatment management.
Press Releases • Jul 11, 2014 23:38 BST
Three new studies presented today at the International Liver CongressTM2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
New advances in hepatocellular carcinoma diagnosis, staging and treatment all predicted to improve patient outcomes
News • Jul 11, 2014 20:55 BST
Wide geographical variation in HCC survival explained by differing intensity of country screening programmes Staging HCC with gadoxetic acid-enhanced MRI improves treatment outcomes in patients with early disease Novel gene signature able to predict development of HCC in high-risk individuals Radiofrequency ablation effective in treating both small HCC and advanced disease
Metabonomics and Protoemics Generate the Opportunity for Novel Screening Tests for Hepatocellular Carcinoma and Cholangiocarcinoma
News • Jul 10, 2014 22:34 BST
New data from two clinical trials presented today at the International Liver Congress™ 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) using diagnostic urine tests.
Press Releases • Jul 09, 2014 11:57 BST
EASL Premium Sponsors support all EASL activities and programmes throughout the year providing funding for Schools of Hepatology, Fellowships, Bursaries, Monothematic Conferences, Special Conferences, Webcasting, e-Series and the EASL EU Framework Programme. These are announced as Bristol Myers Squibb, Gilead and AbbVie.
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C
Press Releases • Jul 09, 2014 00:40 BST
If Approved, Sofosbuvir Would Be the First All-Oral Treatment Regimen for Patients in Japan with Genotype 2 HCV
Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients
Press Releases • Jul 09, 2014 00:26 BST
- Results of the HALLMARK-Dual study include data among genotype 1b cirrhotic and non-cirrhotic, treatment-naïve, non-responder, and peginterferon/ribavirin ineligible and intolerant patients - Study reinforces the potential of daclatasvir-based regimens to treat HCV patients with high unmet needs - Data to be presented during late-breaker session at EASL The International Liver CongressTM
Press Releases • Jul 01, 2014 01:00 BST
As the 2015 International Liver Congress opens its doors in Vienna, we are providing you with this year's Media Kit that will include materials to be circulated to the media. All queries regarding the Media materials or the EASL Press Office should be directed to the EASL press office via email or telephone +44 207 331 5472 Pictures of the congress are available
About EASL European Association for the Study of the Liver
EASL, the leading liver association in Europe
Since 1966, when the association was founded, EASL has continued to grow from a small organisation that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in european liver policies.
- EASL European Association for the Study of the Liver
- 7 rue Daubin
- 1203 Geneva
- Our homepage